GenomeDx's Decipher® Test and Decipher GRID™ to be Featured in Five Presentations at Society of Urologic Oncology

Nov 25, 2015, 15:30 ET from GenomeDx Biosciences

SAN DIEGO, Nov. 25, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that data from several of its programs will be presented at the Society of Urologic Oncology's 16th Annual Meeting, held Dec. 2-4 in Washington, D.C. Five presentations will highlight data from the Decipher® Prostate Cancer Classifier, Decipher Genomic Resource Information Database (Decipher GRID™) and the company's research on bladder cancer.

Wednesday, Dec. 2
Session I: 4:30 p.m. to 6 p.m. EST

Title: Validation of a Genomic Classifier for prediction of metastasis following postoperative salvage radiation therapy
Presenter: Robert Den, M.D., assistant professor of radiation oncology and cancer biology at Thomas Jefferson University
Poster Number: 74

Title: Validation of a Genomic Classifier for predicting post-prostatectomy recurrence in a community based health care setting
Poster Number: 78

Title: Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk
Presenter: Ashley Ross, M.D., Ph.D., associate professor of urology and oncology, Johns Hopkins School of Medicine
Poster Number: 106

Title: B7H3 expression is androgen related and predictive of prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy
Presenter: Ashley Ross, M.D., Ph.D., associate professor of urology and oncology, Johns Hopkins School of Medicine
Poster Number: 105

Friday, Dec. 4
Young Urologic Oncologists Program: 4:30 p.m. to 6 p.m. EST

Title: Can bladder cancer gene expression signatures be used to predict lymph node metastasis at the time of radical cystectomy?
Presenter: Roland Seiler, M.D., University of British Columbia
Presentation Number: 1

About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by radiation oncologists and urologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.

Learn more at www.DecipherTest.com 

About Decipher GRIDTM
The Decipher Genomic Resource Information Database (Decipher GRID™) is the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GRID unifies a patient's whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID will use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data.

Learn more at www.DecipherGRID.com

About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx's Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRID, the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia.

Learn more at www.GenomeDx.com

Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com

 

SOURCE GenomeDx Biosciences



RELATED LINKS

http://genomedx.com